ArticleFrontiers in endocrinology2025
Back to normal? A retrospective study on stimulation test and endocrinological diagnosis before, during and after COVID-19 pandemics.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in central precocious puberty incidence in Japan during the COVID-19 pandemic.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The COVID-19 pandemic disrupted healthcare systems, affecting consultations and diagnostics. In pediatric endocrinology, referral patterns shifted, with increased central precocious puberty (CPP) diagnoses and decreased growth hormone deficiency (GHD) evaluations. This study examines trends in stimulation tests, referrals, and diagnoses from 2019 to 2023 to assess the pandemic's impact on pediatric endocrinology. Methods: This retrospective study analyzed stimulation tests performed at the Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, from 2019 to 2023, divided into pre-pandemic (2019-March 2020), pandemic (March 2020-January 2022), and post-pandemic (February 2022-December 2023) phases. Results: A total of 1,526 tests were conducted on 1,042 patients. Tests per day remained stable (pre-pandemic: 0.84; pandemic: 0.82; post-pandemic: 0.85). The Arginine Stimulation Test (ATT), the most frequent test pre-pandemic (31%), decreased during the pandemic (20%, p<0.001), while the LHRH Test (LHRHT) increased from 22% to 28% (p<0.001), becoming the most requested test. Diagnosis rates for GHD and CPP remained stable, but the proportion of females diagnosed with CPP increased significantly during the pandemic (91% vs. 69%, p=0.022). CPP testing declined (p=0.018) post-pandemic, while GHD testing returned to pre-pandemic levels. Conclusion: The pandemic altered diagnostic patterns, with reduced GHD evaluations reflecting limited healthcare access. Post-pandemic recovery suggests a resolution of diagnostic delays. The temporary surge in CPP cases, likely influenced by pandemic-related lifestyle changes, subsided post-pandemic, aligning with pre-pandemic trends. To date, no other studies have reported similar variations in GHD incidence during the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.